Racura presents MYC silencing data at AACR 2026
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Racura Oncology Ltd announced the presentation of data on MYC gene silencing at the AACR Annual Meeting, detailing how (E,E)-bisantrene stabilizes G-quadruplex structures in the c-MYC gene promoter, leading to gene silencing. The data supports Racura's ongoing and planned clinical trials, highlighting the mechanism of action of their lead asset (E,E)-bisantrene. Dr. Sumit Sahni presented the findings, which were well-received at the conference, indicating strong interest in Racura's research.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Racura Oncology
- First Patient Recruited to HARNESS-1 Lung Cancer Trial
- First Patient Dosed Safely with RC220 in Hong Kong
- Racura HARNESS-1 Trial Receives Governance Approval
- Appendix 4D & Half-Year Financial Statements
- Racura Develops Novel Cardioprotection Blood Test
Later from Racura Oncology
- March 2026 Quarterly Activity Report and Appendix 4C
- (E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression
- CPACS Trial Cleared to Escalate to Next RC220 Dose Level
- Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
- Racura Enters Underwriting Agreement for Options
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology